Your browser doesn't support javascript.
loading
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor, A; van Rossum, J A; Leurs, C; Wattjes, M P; Rispens, T; Murk, J L A N; Uitdehaag, B M J; Killestein, J.
Afiliação
  • Vennegoor A; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
  • van Rossum JA; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
  • Leurs C; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
  • Wattjes MP; Department of Radiology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
  • Rispens T; Landsteiner Laboratory, Sanquin Research, Amsterdam, The Netherlands.
  • Murk JL; Department of Medical Microbiology, UMC Utrecht, Utrecht, The Netherlands.
  • Uitdehaag BM; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
  • Killestein J; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
Eur J Neurol ; 23(6): 1079-85, 2016 06.
Article em En | MEDLINE | ID: mdl-27018481
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucoencefalopatia Multifocal Progressiva / Vírus JC / Esclerose Múltipla Recidivante-Remitente / Natalizumab / Fatores Imunológicos / Anticorpos Antivirais Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucoencefalopatia Multifocal Progressiva / Vírus JC / Esclerose Múltipla Recidivante-Remitente / Natalizumab / Fatores Imunológicos / Anticorpos Antivirais Idioma: En Ano de publicação: 2016 Tipo de documento: Article